{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:16:03Z","timestamp":1788030963624,"version":"build-2784847793"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":229,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA) expression has been demonstrated in the tumor microenvironment of high-grade gliomas (HGG). Here, we assessed the utility of PSMA-positron emission tomography (PET) imaging in patients with HGG for radiation therapy (RT) planning and in differentiating tumor progression from post-treatment changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with HGG (WHO grade 3-4) were included in our prospective PET imaging registry. Analysis was stratified into two cohorts based on clinical indication for PET\u2014Cohort A: RT planning; and Cohort B: evaluation of suspected recurrence. PSMA avidity was quantified using standardized uptake value (SUV) measurements including absolute maximum SUV(SUVmax), and SUV ratio referencing right parotid (SUVRp), and superior sagittal sinus (SUVRsss).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-seven patients were included (Cohort A, N\u2009=\u200919; Cohort B, N\u2009=\u20098). In Cohort A, all MRI T1 contrast-enhancing lesions were PET avid; with PSMA-avid volume exceeding MRI T1 contrast-enhancing volume in 4 patients (20%). The respective mean lesion SUVmax, SUVRp, and SUVRsss for patients with PSMA avid disease (n\u2009=\u200917) vs those without (n\u2009=\u20092) were 7.2 vs 1.5 (P\u2009=\u2009.002); 0.6 vs 0.2 (P\u2009=\u2009.008); and 6.5 vs 1.8 (P\u2009=\u2009.008). Post-RT mean SUVmax decreased by 25.8% (6.2 to 4.6, P\u2009=\u2009.005). In Cohort B, PSMA PET accurately identified pathologically confirmed tumor progression (n\u2009=\u20096, mean SUVmax 7.0) and necrosis (n\u2009=\u20091, SUVmax 1.5) in 88% patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PSMA PET avidity, particularly SUVmax, is higher in glioblastoma multiforme (GBM) patients with residual tumor or tumor progression. These findings suggest a potential role for PSMA PET in tumor delineation, aiding in comprehensive coverage of tumor volumes for radiation planning and response assessment to differentiate tumor progression and post-treatment changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag217","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:33:21Z","timestamp":1786707201000},"source":"Crossref","is-referenced-by-count":0,"title":["Prostate specific membrane antigen (PSMA) PET\/CT for radiation planning and response assessment in intracranial high-grade gliomas"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4079-1268","authenticated-orcid":false,"given":"Rituraj","family":"Upadhyay","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Moffitt Cancer Center , Tampa, Florida,","place":["USA"]},{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Moffitt Cancer Center , Tampa, Florida,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingfeng","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology and Nuclear Medicine, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Bello-Pardo","sequence":"additional","affiliation":[{"name":"Ohio State University College of Medicine , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Mohtashami","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5165-0984","authenticated-orcid":false,"given":"Pierre","family":"Giglio","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0009-5049","authenticated-orcid":false,"given":"Kyle C","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Brad","family":"Elder","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Beyer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju R","family":"Raval","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M","family":"Thomas","sequence":"additional","affiliation":[{"name":"Renaissance Institute of Precision Oncology & Radiosurgery , Orlando, Florida,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, Minnesota,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6470-5400","authenticated-orcid":false,"given":"Jana","family":"Ivanidze","sequence":"additional","affiliation":[{"name":"Department of Radiology, Weill-Cornell Medicine , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-0129","authenticated-orcid":false,"given":"Joshua D","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center , Columbus, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026082914361154500_vdag217-B1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026082914361154500_vdag217-B2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026082914361154500_vdag217-B3","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"2026082914361154500_vdag217-B4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1215\/15228517-2009-005","article-title":"Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma","volume":"11","author":"Pirzkall","year":"2009","journal-title":"Neuro Oncol"},{"key":"2026082914361154500_vdag217-B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-018-2896-3","article-title":"Earliest radiological progression in glioblastoma by multidisciplinary consensus review","volume":"139","author":"Eijgelaar","year":"2018","journal-title":"J Neurooncol"},{"key":"2026082914361154500_vdag217-B6","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1016\/j.prro.2024.04.009","article-title":"Additive value of magnetic resonance simulation before chemoradiation in evaluating treatment response and pseudoprogression in high-grade gliomas","volume":"14","author":"Yadav","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"2026082914361154500_vdag217-B7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11060-017-2375-2","article-title":"Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape","volume":"134","author":"Ellingson","year":"2017","journal-title":"J Neurooncol"},{"key":"2026082914361154500_vdag217-B8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nic.2020.09.010","article-title":"Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis","volume":"31","author":"Strauss","year":"2021","journal-title":"Neuroimaging Clin N Am"},{"key":"2026082914361154500_vdag217-B9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082914361154500_vdag217-B10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","article-title":"Initial experience of (68)Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy","volume":"69","author":"Bud\u00e4us","year":"2016","journal-title":"Eur Urol"},{"key":"2026082914361154500_vdag217-B11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11060-018-2825-5","article-title":"Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody","volume":"138","author":"Matsuda","year":"2018","journal-title":"J Neurooncol"},{"key":"2026082914361154500_vdag217-B12","doi-asserted-by":"publisher","first-page":"646387","DOI":"10.3389\/fonc.2021.646387","article-title":"PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging","volume":"11","author":"Holzgreve","year":"2021","journal-title":"Front Oncol"},{"key":"2026082914361154500_vdag217-B13","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1097\/RLU.0000000000002280","article-title":"Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in cerebral radionecrosis: implications for diagnostic imaging of high-grade gliomas","volume":"43","author":"Salas Fragomeni","year":"2018","journal-title":"Clin Nucl Med"},{"key":"2026082914361154500_vdag217-B14","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/RLU.0000000000001451","article-title":"Diagnostic value of 68Ga PSMA-11 PET\/CT imaging of brain tumors-preliminary analysis","volume":"42","author":"Sasikumar","year":"2017","journal-title":"Clin Nucl Med"},{"key":"2026082914361154500_vdag217-B15","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1097\/RLU.0000000000002668","article-title":"18F-PSMA 1007 brain PET\/CT imaging in glioma recurrence","volume":"45","author":"Marafi","year":"2020","journal-title":"Clin Nucl Med"},{"key":"2026082914361154500_vdag217-B16","doi-asserted-by":"publisher","first-page":"9256","DOI":"10.1038\/s41598-022-13467-9","article-title":"Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET\/MRI analysis in patients with meningioma","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"key":"2026082914361154500_vdag217-B17","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/neuonc\/noae067","article-title":"[Ga68] DOTATATE PET\/MRI-guided radiosurgical treatment planning and response assessment in meningiomas","volume":"26","author":"Ivanidze","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026082914361154500_vdag217-B18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41598-021-04613-w","article-title":"Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging","volume":"12","author":"Kunikowska","year":"2022","journal-title":"Sci Rep"},{"key":"2026082914361154500_vdag217-B19","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2967\/jnumed.123.265738","article-title":"PET imaging and protein expression of prostate-specific membrane antigen in glioblastoma: a multicenter inventory study","volume":"64","author":"Lith","year":"2023","journal-title":"Journal of Nuclear Medicine"},{"key":"2026082914361154500_vdag217-B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases","volume":"14","author":"Nomura","year":"2014","journal-title":"Cancer Cell Int"},{"key":"2026082914361154500_vdag217-B21","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","article-title":"Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme","volume":"135","author":"Wernicke","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"2026082914361154500_vdag217-B22","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1007\/s00259-025-07338-4","article-title":"PSMA radioligand uptake correlates with PSMA expression in high-grade glioma and brain metastasis: insights from a prospective PET-MRI guided multiregional biopsy study","volume":"52","author":"Pruis","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026082914361154500_vdag217-B23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms242216208","article-title":"Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as imaging biomarkers in adult recurrent glioblastoma","volume":"24","author":"Brighi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026082914361154500_vdag217-B24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2967\/jnumed.122.264803","article-title":"Utility of amino acid PET in the differential diagnosis of recurrent brain metastases and Treatment-Related changes: a meta-analysis","volume":"64","author":"Schl\u00fcrmann","year":"2023","journal-title":"J Nucl Med"},{"key":"2026082914361154500_vdag217-B25","doi-asserted-by":"publisher","first-page":"e071327","DOI":"10.1136\/bmjopen-2022-071327","article-title":"[18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET\/CT trial","volume":"13","author":"Koh","year":"2023","journal-title":"BMJ Open"},{"key":"2026082914361154500_vdag217-B26","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.3390\/jcm10112313","article-title":"Role of 11C methionine positron emission tomography (11CMETPET) for surgery and radiation therapy planning in newly diagnosed glioblastoma patients enrolled into a phase II clinical study","volume":"10","author":"Pessina","year":"2021","journal-title":"J Clin Med"},{"key":"2026082914361154500_vdag217-B27","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2967\/jnumed.122.264812","article-title":"Distinguishing progression from pseudoprogression in glioblastoma using 18F-Fluciclovine PET","volume":"64","author":"Nabavizadeh","year":"2023","journal-title":"J Nucl Med"},{"key":"2026082914361154500_vdag217-B28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/jpm11070624","article-title":"PSMA expression in 122 treatment naive glioma patients related to tumor metabolism in 11C-methionine PET and survival","volume":"11","author":"Traub-Weidinger","year":"2021","journal-title":"J Pers Med"},{"key":"2026082914361154500_vdag217-B29","doi-asserted-by":"publisher","first-page":"101548","DOI":"10.1016\/j.adro.2024.101548","article-title":"Comparative analysis of recurrent glioblastoma target contours via 11C-methionine, 68Ga-prostate-specific membrane antigen positron emission tomography, and magnetic resonance imaging: implications for precision radiotherapy planning","volume":"9","author":"Ferini","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"2026082914361154500_vdag217-B30","doi-asserted-by":"publisher","first-page":"774017","DOI":"10.3389\/fonc.2021.774017","article-title":"PSMA PET imaging in glioblastoma: a preclinical evaluation and theranostic outlook","volume":"11","author":"Kirchner","year":"2021","journal-title":"Front Oncol"},{"key":"2026082914361154500_vdag217-B31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00259-020-04715-z","article-title":"Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026082914361154500_vdag217-B32","doi-asserted-by":"publisher","first-page":"892","DOI":"10.2967\/jnumed.122.264850","article-title":"[177Lu]Lu-PSMA therapy as an individual treatment approach for patients with high-grade glioma: dosimetry results and critical statement","volume":"64","author":"Graef","year":"2023","journal-title":"J Nucl Med"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag217\/70673504\/vdag217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag217\/70673504\/vdag217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag217\/70673504\/vdag217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:36:30Z","timestamp":1788028590000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag217\/8762950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag217","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"vdag217"}}